DCA

DCA
Name	DCA
Other names	dichloroacetate
Formula	C2HCl2O2
Molar mass	128.94 g/mol
Routes of administration	oral, intravenous
Legal status	varies by jurisdiction

DCA is the common abbreviation for dichloroacetate, a small organochlorine compound investigated for metabolic modulation and rare disease therapy. It has attracted attention across biochemical, clinical, and translational research communities for effects on mitochondrial metabolism, with applications ranging from inborn errors of metabolism to oncology and neuroprotection. Research interest spans academic laboratories, biotechnology companies, clinical trial networks, and patient advocacy groups.

Definition and Terminology

Dichloroacetate appears in chemical literature under names used by IUPAC, Chemical Abstracts Service, and pharmacopoeias. Synonyms encountered in pharmaceutical and toxicological documents include 2,2-dichloroacetic acid and chloral-derived nomenclature used by Merck Index, PubChem, and national formularies. In clinical trial registries maintained by National Institutes of Health and regulatory agencies such as the European Medicines Agency and Food and Drug Administration, dichloroacetate is often listed alongside investigational agent identifiers and investigational new drug applications. In biochemical pathway diagrams produced by groups at Harvard Medical School, University of Cambridge, and Massachusetts Institute of Technology, the compound is referenced in relation to enzymes cataloged by UniProt and reactions annotated in KEGG.

History and Development

Interest in dichloroacetate dates to mid-20th century inorganic and organochlorine chemistry studies from laboratories at University of Oxford and industrial research by firms like DuPont and BASF. Early toxicology and metabolic research at Johns Hopkins University and University of California, San Francisco characterized pharmacokinetics and tissue distribution. Clinical exploration began with metabolic studies in patients with congenital lactic acidosis and investigations by researchers affiliated with McGill University and University of Toronto. Oncological interest was catalyzed by preclinical studies from groups at University of Alberta and University College London showing effects on tumor cell mitochondrial function, prompting investigator-initiated trials at institutions including Mayo Clinic, Memorial Sloan Kettering Cancer Center, and academic hospitals in Brazil and Italy.

Mechanism of Action and Chemistry

Dichloroacetate acts biochemically as an inhibitor of pyruvate dehydrogenase kinase isoforms characterized in studies at Max Planck Society and Salk Institute. By inhibiting those kinases, dichloroacetate stimulates the pyruvate dehydrogenase complex components annotated by Ensembl and UniProt, shifting pyruvate flux toward mitochondrial oxidative decarboxylation—a mechanism examined in metabolic flux analyses at Stanford University and MIT. Chemical properties such as acid dissociation constants and halogen effects were detailed in physical chemistry work from California Institute of Technology and ETH Zurich. Structural biology efforts using X-ray crystallography at facilities like Diamond Light Source and European Synchrotron Radiation Facility informed interactions with kinase active sites, while metabolomics collaborations involving European Bioinformatics Institute and Metabolomics Workbench mapped downstream effects on tricarboxylic acid cycle intermediates cataloged by HMDB.

Clinical and Research Applications

Clinically, dichloroacetate has been studied in inherited mitochondrial disorders such as pyruvate dehydrogenase complex deficiency and mitochondrial encephalomyopathies in trials coordinated by centers like Great Ormond Street Hospital and Children's Hospital of Philadelphia. Oncology research evaluated dichloroacetate in tumor metabolism modulation across studies at University of Texas MD Anderson Cancer Center, Vanderbilt University Medical Center, and cooperative groups registered with ClinicalTrials.gov. Neuroprotection experiments conducted at Columbia University and Karolinska Institutet examined ischemia models and neurodegenerative conditions. Preclinical pharmacology and combination therapy research involved collaborations with biotech firms including Novartis and academic spin-outs from University of Cambridge, exploring synergies with agents approved by NICE and guidelines cited by American Society of Clinical Oncology.

Safety, Side Effects, and Contraindications

Safety data originate from clinical trials, case series, and toxicology reports compiled by agencies such as World Health Organization and national drug agencies. Reported adverse effects include peripheral neuropathy described in cohorts at Royal College of Physicians and reversible hepatic enzyme elevations documented in studies at University of Paris. Contraindications and cautions were discussed in consensus statements from specialist societies including European Society of Paediatric Research and metabolic disease networks like United Mitochondrial Disease Foundation. Drug interaction assessments incorporated data standards from DrugBank and pharmacovigilance reporting systems run by EudraVigilance and FDA Adverse Event Reporting System.

Regulatory Status and Availability

Regulatory evaluation of dichloroacetate has varied: some national regulatory bodies reviewed investigator-initiated trial applications while others have not approved marketing authorizations. Regulatory dossiers and orphan designation discussions occurred with EMA and national authorities; compassionate use and named-patient supply programs involved hospital pharmacies at University Hospitals Bristol and specialized centers in Canada and Australia. Commercial availability for research use is offered by chemical suppliers listed in databases like ChemSpider and Sigma-Aldrich catalogs, whereas clinical-grade formulations require oversight comparable to procedures used by Good Manufacturing Practice certified manufacturers.

Category:Organochlorides